Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL

(MedPage Today) -- NEW ORLEANS--Consolidation chemotherapy with blinatumomab (Blincyto) improved overall survival (OS) in patients with newly diagnosed measurable residual disease (MRD)-negative B-lineage acute lymphoblastic leukemia (ALL)...